Latest KFF Health News Content

Latest KFF Health News Stories

Washington State Law On Behavioral Care Balances Parental Rights, Teens’ Autonomy

KFF Health News Original

Many states have rules that keep parents from knowing about or consenting to certain types of care for their children, including mental health and drug and alcohol treatment. Washington state, however, has revised its policies.

No Matter How Successful They Are, Drugs With Million-Dollar Price Tags Are Unsustainable, CMS Chief Says

Morning Briefing

CMS Administrator Seema Verma spoke of her concerns about drugs that cost upwards of $2 million. That kind of innovation doesn’t mean anything if people can’t afford the treatment, Verma said. In other news from CMS, the agency announced it would crack down on nursing home inspectors.

What’s Behind Rise Of STDS Among Young People?: Epidemic Alarms Health Officials As Prevention Funding Drops

Morning Briefing

CDC officials say they’re not sure why younger people who are having less sex are acquiring more STDS, but a new bill moving through the House to increase spending on STD prevention could help. Public health news is on CBD, pros and cons of genetic tests, limiting sports time for teens, childhood obesity, insecticides, getting young kids hooked on sugar, smart aging, and dementia, as well.

Despite Intense Scrutiny, Doctors Still Receiving Astronomical Sums From Drug and Medical Device Companies

Morning Briefing

An analysis by ProPublica reveals that more than 2,500 physicians received at least half a million dollars apiece from drugmakers and medical device companies in the past five years alone. More than 700 of those doctors received at least $1 million. In other news on the health industry, costs and insurance: workers’ benefits, refunds from insurers, out-patient surgery policies, universal coverage, and more.

In Latest Round Of Legal Woes, Johnson & Johnson Agrees To $117M Multi-State Settlement Over Pelvic Mesh Products

Morning Briefing

Numerous women who had the once-popular, hammock-like devices implanted claim they caused severe pain, bleeding, infections and other complications. About 25,000 U.S. women with complications have sued Johnson & Johnson, the company said. Those lawsuits aren’t affected by the settlement.

As Border Patrol Agents Become A Common Feature At Hospitals, Medical Professionals Struggle To Preserve Patients’ Rights

Morning Briefing

Earlier this year, the agency that oversees Border Patrol said its agents averaged 69 trips to the hospital each day across the country. Although hospitals have typically been treated as “sensitive locations” that are generally free of immigration enforcement, the rule is discretionary and ambiguous when an enforcement action begins before a trip to a hospital or when an immigrant is already in custody.

In High-Stakes Move Before Opioid Case Goes To Trial, Judge Summons CEOs To Eleventh-Hour Talks With Plaintiffs

Morning Briefing

Judge Dan Polster, who is overseeing the nationwide opioid case against drug companies and distributors for their alleged role in the epidemic, wants the sides to come to a resolution before it goes to court. The trial is set to kick off on Monday if talks fall through. While the negotiations center around the major players — AmerisourceBergen, Cardinal Health and McKesson — plaintiffs’ lawyers say they hope such a deal would have a domino effect on the remaining defendants.

Juul Temporarily Halts Online Sales Of Flavored E-Cigarettes, But Critics Say That’s Far From Enough

Morning Briefing

Data shows “that 64 percent of high school e-cigarette users now use mint or menthol flavors and this number is growing all the time,” said Matthew Myers, president of the Campaign for Tobacco-Free Kids. However others said Juul’s decision to halt sales of flavors like manjo, crème, fruit and cucumber would hurt adult smokers. Meanwhile, the cases of the vaping-related lung illness continue to climb.

Pelosi’s Signature Drug Plan Marches Forward Even As Speaker Clashes With Trump On Other Issues

Morning Briefing

Lawmakers bickered over the pros and cons — “jaw dropping savings” that come with a warning that some pharma companies may not develop as many new drugs — but in the end House Speaker Nancy Pelosi’s drug plan passed out of the House Energy and Commerce Committee as well as the Education and Labor Committee. There had been a chance that Pelosi could get President Donald Trump on board as he’s previously supported the proposals in the plan. But that became less certain in recent days with the impeachment proceedings.